Skip to main content
OpenTrials
Completed

NCT Number: NCT02872064

Treatment of Primary Breast Cancer Using PDT

Phase I/IIA, open label, non-randomised, single site trial in patients with primary breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

30 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Royal Free Hospital

London, NW3 2QG, United Kingdom

About this study

This is a phase I / IIa study recruiting patients diagnosed with primary breast cancer. Patients who have chosen mastectomy or wide local excision as their surgical option will be included. Patients will have a pre therapy MRI followed by photodynamic therapy. PDT involves intravenously injecting the photosensitizer Verteporfin (Visudyne) drug. This drug makes the tumour sensitive to light. A non-thermal light will then be shone in the tumour which brings about tissue necrosis (destruction). Although the drug dose will remain the same, the light dose will be escalated depending on patient response in accordance to a predefined algorithm (see section) to achieve a zone of necrosis of 12mm or a plateau of necrosis with incremental increase in light dose. An MRI will be performed immediately prior to the scheduled surgery. Pre and post PDT MRI changes will be correlated with the histological findings on the excised breast specimen. Should the minimum light dose for 12mm necrosis be established recruitment will continue until 12 patients have received this dose. These 12 patients will provide sample data on the size of tumour and area of necrosis detected by MRI and histology to enable sample size (power) calculations for future studies of PDT in primary breast cancer. This is a dose escalation study involving a minimum of twelve and a maximum of forty patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 30 or over
  • A uni-focal invasive ductal breast carcinoma or discrete uni-focal site which is deemed suitable for PDT within a multifocal invasive ductal carcinoma in a single breast.
  • Patients who have opted for mastectomy or wide local excision as primary treatment.
  • Capable of giving written informed consent

Exclusion criteria

  • Patients who are not undergoing surgery as their primary treatment.
  • Patients undergoing surgery for DCIS without invasive breast cancer.
  • Patients with Lobular cancer
  • Patients with Necrotic tumours
  • Distant metastatic disease.
  • Patients will be excluded if they have porphyria or are sensitive to verteporfin (visudyne).
  • Patients who have severe cardiovascular disease.
  • Patients with severe or uncontrolled systemic disease e.g. hepatic impairment.
  • Patients with laboratory findings that make it undesirable for the patient to participate in the trial.
  • Male breast cancer patients
  • Pregnancy and lactation.
  • No patients with any psychiatric disorder making reliable informed consent impossible.
  • Patients will be excluded if taking part in any other trial of an experimental medicine
  • Patients will be excluded if taking endocrine therapy drugs that could confound the results.

Treatment and study plan

Verteporfin

Drug

Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.

Other names: Visudyne

Primary outcomes

  1. Establish the minimum effective light dose

    Time frame: One month

    To establish the minimum light dose, in the range 20Joules/ (cm of light diffuser length) but not exceeding 90J/cm, required to induce an area of necrosis with a diameter of at least 12mm in line perpendicular to the fibre on microscopic examination or to achieve a plateau with no increasing necrosis as the light dose increases.

Secondary outcomes

  1. Compare final histology with post PDT MRI.

    Time frame: One month

    To assess the response of the Photodynamic Therapy on primary breast cancer via radiology using pre and post PDT MRI and comparing this with final histology. Measurements will be made of the diameter of necrosis on MRI scan which will be correlated with the histological measurement.

  2. Assess affect of PDT on normal breast tissue.

    Time frame: One month

    To look at the effect of Photodynamic Therapy on the abnormal breast tissue and study if necrosis extends to normal breast tissue.

Sponsors and collaborators

Lead sponsor

University College, London

Other

Registry information

Official study title

A Phase I/IIa, Open Label, Single Site Light Dose Escalation Trial of Single Dose Verteporfin Photodynamic Therapy (PDT) in Primary Breast Cancer

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Aug 18, 2016
Registry last updated
Apr 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.